


OUR COMPANY

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies.



Founded in 1885 in Ingelheim and family-owned to this day



~50,000 employees worldwide

FOCUS ON



Human pharmaceuticals



Animal health



Biopharmaceuticals

SUCCESSFUL BUSINESSES

HUMAN PHARMACEUTICALS

EUR **12,621 million**
TOTAL NET SALES
IN 2017

FOCUS ON



Respiratory diseases



Cardiomicrobial diseases



Central nervous system + immunology



Oncology

ANIMAL HEALTH



GLOBAL PLAYER

EUR **3,901 million**
TOTAL NET SALES
IN 2017

SHARE

54% COMPANION ANIMALS

46% LIVESTOCK



49% PETS



16% CATTLE



18% SWINE



11% POULTRY



5% EQUINE

1% OTHER

BIOPHARMACEUTICAL CONTRACT MANUFACTURING

Boehringer Ingelheim is a world-leading contract manufacturer of biopharmaceuticals.

We operate

1

GLOBAL NETWORK



of biopharmaceutical production sites in Europe, the USA and Asia

We are a pioneer in biopharmaceuticals WITH OVER

35

YEARS of experience

EUR **678 million**
TOTAL NET SALES 2017

We have manufactured MORE THAN

25

BIOPHARMACEUTICALS for global markets

SUSTAINABLE ECONOMIC & SCIENTIFIC ACTIVITY

ECONOMIC SUCCESS (2017)

EUR **18,056 million**
NET SALES

19.3%
RETURN ON NET SALES

AMERICAS



EUR **8,141 million**

EUROPE



EUR **5,690 million**

ASIA, AUSTRALIA, AFRICA (AAA)



EUR **4,225 million**

RESEARCH & DEVELOPMENT

EUR **2,714 million**

Human Pharmaceuticals expenditure in research & development in 2017

3 PILLARS



Focus on research therapeutic areas



Scientific platforms



Research Beyond Borders

≈ around **21.5%** of Human Pharmaceuticals net sales 2017

SOCIAL RESPONSIBILITY

MAKING MORE HEALTH



ASHOKA

Making More Health is a global initiative by Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organisation. Its aim is to improve healthcare for people worldwide.

MORE THAN

85

social entrepreneurs in over 30 countries received support since 2010

APPROX.

5,000

Boehringer Ingelheim employees worldwide are involved in the initiative

DIVERSITY & INCLUSION DRIVE INNOVATION

48% women*

36% female leaders*

35% GENERATION Y (1981-2000)*



17% BABY BOOMERS (1946-1964)*

48% GENERATION X (1965-1980)*

*Boehringer Ingelheim worldwide, 2017

DIVERSITY IS NOT ONLY ABOUT



Minorities



Individuals



Compliance/ethics



Balance



Team composition



Innovation/growth

DIVERSITY IS ALSO ABOUT